NLS Biotech News

Cereno Scientific has signed an agreement with medical technology company Fluidda on Respiratory Imaging solutions, with the aim to visualize signs of reverse remodeling of lead drug candidate CS1 in Pulmonary Arterial Hypertension (PAH) in a clinical setting.

Anocca will present its novel platform approach to therapeutic TCR discovery and preclinical data for its lead TCR-T cell therapy product at the European Society of Medical Oncology (ESMO) Congress 2024.

The results further demonstrate the potential for TILT-123 as an intravenous therapy.

The company has agreed with the investigators conducting the LUNGVAC trial to discontinue patient recruitment.

Medivir has presented positive, mature data from its ongoing phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced liver cancer at the ESMO Congress in Barcelona, Spain.

Evaxion Biotech has announced new clinical phase 2 data for its lead compound EVX-01.

Cantargia has reported data from two clinical trials including nadunolimab combination therapy in 55 cancer patients.

“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there are many existing biomarkers and faster trials,” says Medaffcon’s Scientific Advisor, PhD Riikka Mattila. According to Mattila, Medaffcon can assist pharmaceutical companies in their research […]

Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC). In short, the result showed that 86 percent overall reduction of tumor size, 51 percent complete clearance rate of basal cell carcinomas (total removal), and 71 percent average reduction in tumor size of patients with […]

Affibody’s partner ACELYRIN has announced that the Phase 3 trial of the Affibody molecule izokibep in patients with hidradenitis suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as well as the key secondary endpoints of HiSCR90 and HiSCR100. “We are delighted that the Phase 3 HS trial of izokibep was successful, again confirming […]